References
1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26 (11):1054-9.
2. Aurangzeb S, Tariq M, Irshad M, Badshah M, Khan RS. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc. 2009;59(5):289-92.
3. Feng HY, Wang HY, Liu WB, He XT, Huang X, Luo CM, et al. The high frequency and clinical feature of seronegative myasthenia gravis in Southern China. Neurol Sci. 2013.
4. Gao F, Zhao X, Zhang J, Cui X, Zhang Y, Li Q, et al. Clinical features of patients with Myasthenia gravis from the Henan province, China. Muscle & nerve. 2016.
5. Chiu H, Vincent A, Newsom-Davis J, Hsieh K, Hung T. Myasthenia gravis Population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37(12):1854-.
6. Xu J, Yang M, Li B, Jiang H, Zhang R, Xu S. Myasthenia gravis: clinical study in 2385 patients. Chin J Neurol. 1999;32(6):347-50.
7. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai journal of medicine, New York. 1971;38(6):497.
8. Ashraf V, Taly A, Vasanth A, Veerendrakumar M, Rao S. Myasthenia Gravis: Clinical Spectrum And Long Term Follow-Up Study. Annals of Indian Academy of Neurology. 2005;8(1):7.
9. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol. 2013;20(2):309-14.
10. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of Myasthenia Gravis in Australia. Eur J Neurol. 2012;19(11):1413-20.
11. Bindu PS, Nirmala M, Patil SA, Taly AB. Myasthenia gravis and acetylcholine receptor antibodies: a clinico immunological correlative study on South Indian patients. Ann Indian Acad Neurol. 2008;11(4):242-4.
12. Vincent A, Newsom Davis J. Anti-acetylcholine receptor antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 1980;43(7):590-600.
13. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. Journal of Neurology, Neurosurgery & Psychiatry. 1985;48(12): 1246-52.
14. Soliven B, Lange D, Penn A, Younger D, Jaretzki Ar, Lovelace R, et al. Serone-gative myasthenia gravis. Neurology. 1988;38(4):514-.
15. Sanders DB, Andrews PI, Howard JF, Massey JM. Seronegative myasthenia gra-vis. Neurology. 1997;48(Suppl 5):40S-5S.
16. Limburg P, The T, Hummel-Tappel E, Oosterhuis H. Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 1. Relation to clinical parameters in 250 patients. Journal of the neurological sciences. 1983;58(3):357-70.
17. Compston D, Vincent A, Newsom-Davis J, Batchelor J. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103(3):579-601.
18. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, et al. Different characteristic phenotypes according to antibody in myasthenia gravis. J Clin Neuromuscul Dis. 2012;14(2):57-65.
19. Pasutharnchat N, Wacharapluesadee S, Hemachudha T. Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia gravis. J Med Assoc Thai. 2012;95(3):313-9.
20. Nikolic A, Djukic P, Basta I, Hajdukovic L, Stojanovic VR, Stevic Z, et al. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Clin Neurol Neurosurg. 2013;115(4):432-7.
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.65
